BIO

Jessica Crimaldi, MSN, APRN,CNP, CMSRN was born and raised in the greater Cleveland area. She attended Cleveland State University for her BSN; during her time at CSU she had the opportunity to work at The Cleveland Clinic Foundation in a 3-year internship entitled the "Nursing Experiential Program." In this role she had the opportunity to learn many of the roles on a typical nursing unit while working 1 year as a Unit Secretary, 1 year as a Nurse Assistant and 1 year as a Nurse Intern. She started her nursing career on an inpatient Internal Medicine and Telemetry Teaching Unit where she worked as an RN while completing her MSN at the University of Akron. Since graduation in 2015 she has worked as a Nurse Practitioner in the Department of Gastroenterology, Hepatology and Nutrition seeing inpatients with gastrointestinal and liver disorders at The Cleveland Clinic Foundation. In addition, to her clinical role, she is also the Manager for over 50 Gastroenterology, Hepatology and Nutrition APPs. She is the Co-Director for the nation's first Inflammatory Bowel Disease APP Fellowship which is in its third year. She has presented nationally and published in The Journal for Nurse Practitioners (JNP). She is Faculty for Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) National Organization and Milestone APP. When she is not busy with work Jessica is a wife, parent to 2 young children and dog mom. She is a foster parent and passionate about improving the foster care system. She enjoys being outdoors, hiking and spending time with family and friends.

MASLD-MASH Content Featuring Jessica

Related Content

Serological Workup: A Step-by-Step Guide

July 2025

In this comprehensive video, Sherona Bau, NP from UCLA, breaks down the essential hepatology workup for patients with MASLD (formerly NAFLD) and MASH, offering guidance for both primary care providers and GI/hepatology specialists. Drawing from her extensive clinical experience, she outlines a systematic approach to evaluating abnormal liver ultrasound findings—starting with critical labs to rule out chronic liver conditions like hepatitis B, hepatitis C, autoimmune hepatitis, PBC, and hereditary hemochromatosis. Sherona discusses the importance of ordering ANA, AMA, ferritin, serologies, and even specialized labs like the phosphatidylethanol (PEth) test to uncover alcohol-related liver disease that may be overlooked. She emphasizes the need to screen for cardiometabolic risk factors including type 2 diabetes and dyslipidemia and highlights non-invasive tests such as FibroScan and FIB-4 to help identify patients at risk of advanced fibrosis who may benefit from specialist referral. Most importantly, Sherona addresses the fears many patients face around liver disease progression and life expectancy, encouraging early intervention and coordinated care to improve long-term outcomes. This video is a must-watch for any clinician managing steatotic liver disease.

Watch Now arrow

MASH/MASLD in Type 2 Diabetes: Concurrent Medication Management

July 2025

In this informative episode, Whitney Steinmetz, NP from Presbyterian Medical Group in Albuquerque, NM, explores how to optimize medication strategies for patients with type 2 diabetes who are also living with MASLD and MASH. She discusses why individuals with type 2 diabetes are at significantly higher risk for developing advanced liver fibrosis—highlighting the overlapping metabolic, inflammatory, and insulin-resistant pathways that accelerate liver damage. Whitney breaks down how commonly prescribed diabetes medications—like GLP-1 receptor agonists, SGLT2 inhibitors, TZDs, and dual/triple incretins—impact liver fat, inflammation, and fibrosis progression. She offers practical guidance on selecting therapies that balance glycemic control with hepatic benefits while minimizing polypharmacy. Learn which medications may offer dual cardiometabolic and hepatic advantages, and which should be avoided or used with caution in patients with cirrhosis or advanced fibrosis. Tune in for real-world insights into how advanced practice providers can take ownership of MASH management in diabetes care.

Watch Now arrow